0000899243-20-006973.txt : 20200304
0000899243-20-006973.hdr.sgml : 20200304
20200304172716
ACCESSION NUMBER: 0000899243-20-006973
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200103
FILED AS OF DATE: 20200304
DATE AS OF CHANGE: 20200304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHIERMEIER ANDREW
CENTRAL INDEX KEY: 0001738456
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 20688455
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS
STREET 2: 40 ERIE STREET STE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-03
0
0001652130
Intellia Therapeutics, Inc.
NTLA
0001738456
SCHIERMEIER ANDREW
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET, SUITE 130
CAMBRIDGE
MA
02139
0
1
0
0
EVP, Chief Operating Officer
Common Stock
10316
D
Stock Option (Right to Buy)
13.48
2020-01-03
4
A
0
15000
0.00
A
2020-01-03
2027-01-02
Common Stock
15000
15000
D
Stock Option (Right to Buy)
13.40
2020-03-02
4
A
0
135000
0.00
A
2030-03-01
Common Stock
135000
135000
D
This amount includes 1,672 shares acquired under the NTLA Employee Stock Purchase Plan (912 shares purchased on 6/30/2019 and 760 shares purchased on 12/31/2019).
On January 3, 2017, the reporting person was granted an option to purchase 15,000 shares of common stock. The option vested based on the satisfaction of certain performance criteria. The performance criteria was met, resulting in the vesting of option as to 15,000 shares.
This option was granted on March 2, 2020 with respect to 135,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
/s/ Jose E. Rivera, Attorney-In-Fact
2020-03-04